Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference17 articles.
1. The National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology: non-small cell lung cancer, 2018; version 3.
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp-nscl
.
2. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New Engl J Med. 2010;363(18):1693–703.
https://doi.org/10.1056/NEJMoa1006448
.
3. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–53.
https://doi.org/10.1200/jco.2009.22.6993
.
4. Sun JM, Lira M, Pandya K, et al. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. Lung Cancer (Amsterdam, Netherlands). 2014;83(2):259–64.
https://doi.org/10.1016/j.lungcan.2013.11.009
.
5. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New Engl J Med. 2014;371(23):2167–77.
https://doi.org/10.1056/NEJMoa1408440
.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献